Organogenesis Holdings (STU:2PQ) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2PQ Organogenesis Holdings Inc STU:2PQ
63 GF Score
Price €1.59
GF Value €2.50
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Organogenesis Holdings  (STU:2PQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Organogenesis Holdings Cyclically Adjusted PS Ratio Related Terms


Organogenesis Holdings Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Cyclically Adjusted PS Ratio Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.05

Organogenesis Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.86 1.05 0.48 0.00

STU:2PQ vs AKBA, TKNO, EBS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Cyclically Adjusted PS Ratio falls into.


STU:2PQ
63GF Score
Organogenesis Holdings Inc STU:2PQ
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Organogenesis Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Organogenesis Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.289/333.9520*333.9520
=0.289

Current CPI (Jun. 2026) = 333.9520.

Organogenesis Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 241.428 0.000
201612 3.394 241.432 4.695
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 4.329 246.524 5.864
201803 0.448 249.554 0.600
201806 0.562 251.989 0.745
201809 0.626 252.439 0.828
201812 0.726 251.233 0.965
201903 0.558 254.202 0.733
201906 0.634 256.143 0.827
201909 0.632 256.759 0.822
201912 0.687 256.974 0.893
202003 0.535 258.115 0.692
202006 0.585 257.797 0.758
202009 0.789 260.280 1.012
202012 0.669 260.474 0.858
202103 0.646 264.877 0.814
202106 0.763 271.696 0.938
202109 0.722 274.310 0.879
202112 0.849 278.802 1.017
202203 0.685 287.504 0.796
202206 0.866 296.311 0.976
202209 0.893 296.808 1.005
202212 0.827 296.797 0.931
202303 0.767 301.836 0.849
202306 0.814 305.109 0.891
202309 0.762 307.789 0.827
202312 0.689 306.746 0.750
202403 0.767 312.332 0.820
202406 0.913 314.175 0.970
202409 0.775 315.301 0.821
202412 0.933 315.605 0.987
202503 0.635 319.799 0.663
202506 0.689 322.561 0.713
202509 0.980 324.800 1.008
202512 1.364 324.054 1.406
202603 0.245 330.213 0.248
202606 0.289 333.952 0.289

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €1.59 is trading 36.4% below its estimated GF Value™ of €2.50.

Key valuation signals for STU:2PQ:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €2.50 vs. price of €1.59 (36.4% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organogenesis Holdings Business Description

Other Exchanges ORGO:USA2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
63GF Score

Get the complete analysis for STU:2PQ

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.59
Price
€2.50
GF Value